Glioblastoma (GBM) clinical trials
196 active trials name this condition (recorded in the registry as “Glioblastoma”) . Describe your situation to see which ones you may be eligible for.
Refine by biomarker
By location
- Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
- ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial
- A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma
- Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade Gliomas
- Sitagliptin in Recurrent/Progressive Grade 4 Glioma
- Safety and Efficacy of CTX-009 With or Without CTX-471 for Recurrent Glioblastoma
- Music Therapy in Newly Diagnosed Glioblastoma After Chemoradiation Therapy (MELODY-GBM)
- Omental Tissue Autograft in Human Recurrent Glioblastoma Multiforme (rGBM)
- RNA-Lipid Particle (RNA-LP) Vaccines for Recurrent Adult Glioblastoma (GBM)
- IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Adult Glioblastoma
- First-in Cancer-Type Phase I Study of FT536 for Recurrent WHO Grade 4 Astrocytoma
- Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma
- Precision Radiotherapy Enabled by Molecular MRI
- Neoadjuvant Chemoradiotherapy With or Without Concurrent Azeliragon in Patients With Newly Diagnosed Glioblastoma
- Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma
- Methimazole in Patients With Progressive Glioblastoma
- Study of Liposomal Curcumin in Combination With RT and TMZ in Patients With Newly Diagnosed High-Grade Gliomas
- HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
- HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
- D2C7-IT + 2141-V11 Combination Post-resection in rGBM
- Clinical Trial of BMS-986504 in Recurrent GBM Patients
- A Clinical Trial to Evaluate the Safety, Tolerability and Clinical Efficacy of M3T01 Monotherapy and in Combination With Pembrolizumab and Other Systemic Therapies
- Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma
- GPC-3 CAR T CELLS FOR Recurrent GPC-3 Positive Glioblastoma
- CARv3-TEAM-E T Cells in Glioblastoma
- Sonodynamic Therapy in Patients With Recurrent GBM
- Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM
- Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of the Oncolytic HSV1 MVR-C5252
- A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM
- D2C7-IT and 2141-V11 in Newly Diagnosed GBM Patients
- Surgical Pembro +/- Olaparib w TMZ for rGBM
- Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma
- Study of Low-Intensity Focused Ultrasound in Combination With Immunotherapy in Newly Diagnosed Unmethylated Glioblastoma
- A Phase 0/1 Clinical Trial With an Expansion Phase of GSK5764227, a B7-H3-Targeted Antibody-Drug Conjugate (ADC), in Patients With Recurrent Grade 4 Glioma and Patients With Brain Metastases
- Imaging Acetadote Metabolism in Glioblastoma
- CUE-102 in Recurrent Glioblastoma
- Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma
- Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma
- PH Sensitive MRI Based Resections of Glioblastoma
- Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma
- OPTIMUS PRIME: Safety and Feasibility of OPTune GIO® Integrated With MRI-gUided Laser Ablation Surgery and Pembrolizumab for Recurrent GlIoblastoMa, A randomizEd Trial
- A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
- G-CSF After Chemo-radiation in Patients With Glioblastoma
- DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)
- Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
- Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab
- Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Recurrent Glioblastoma or Recurrent Astrocytoma in Patients Undergoing Craniotomy
- Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma
- Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma
- A Phase 0/1 Study of BDTX-1535 in Recurrent High-Grade Glioma (rHGG) and Newly Diagnosed Glioblastoma (nGBM) Participants With EGFR Alterations or Fusions
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Glioblastoma” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.